Showing promise in the landscape of weight management therapy, retatrutide presents a distinct approach. Unlike many existing medications, retatrutide operates as a dual agonist, at once engaging both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This simultaneous activation encourages various beneficial ef